Анти-Ctla

CTLA4 and attenuation of T cell response

Animated biology With arpan

Beyond anti-PD-1 and anti-CTLA-4 in melanoma

Immune Checkpoint Inhibitors, The Next Generation Cancer Therapy - Creative Biolabs

Creative Biolabs

Mechanism of Action of Anti CTLA4

Interactive Learning

IOU YouTube: How does CTLA-4 prevent T- cell activation?

Dig Deeper Into Immuno-Oncology Research

Dual anti–CTLA-4 and anti–PD-1 blockade in rare tumors (DART) SWOG S1609

Характеристики иммуно-опосредованных побочных эффектов при анти-PD-1и анти-CTLA-4 иммунотерапиях

Клинико-иммунологические аспекты анти-CTLA-4 терапии диссеминированной меланомы (Анохина Е.М.)

НМИЦ онкологии им. Н.Н. Петрова

Decoy-resistant IL-18 plus anti-CTLA-4 blockade for renal cell carcinoma

Anti-PD-1 or anti-CTLA-4 in first line therapy?

JK08, a fusion protein of IL-15 and anti-CTLA-4 antibody, in solid tumors

Cancer Immune Checkpoint Inhibitors

Harvard Medical School Continuing Education

Блокада CTLA-4 и PD1/PDL1 как механизм активации противоопухолевого иммунитета

НМИЦ онкологии им. Н.Н. Петрова

Combining immunotherapies: inhibiting the CTLA-4 and PD-1 pathways

Dr. Fong Discusses Memory T Cell Responses Following Anti-CTLA-4 Antibody Treatment

Targeted Oncology

CTLA-4: The Unwanted Player in Cancer

PATH3309 Cancer Pathology

Challenges to Precision Medicine for Anti-Cancer Immunotherapy

Yale Cancer Center

Exploring the Combination Anti-CTLA-4 and Anti-PD-1 in Multiple Myeloma Post-Transplant

Targeted Oncology

Media CTLA 4 Inhibition

DART vulvar cancer results: dual anti–CTLA-4 and anti–PD-1 blockade in rare tumor